Summary
Hypoglycaemic sulphonylureas bind to multilamellar liposomes formed of egg yolk phosphatidylcholine. In this artificial model, both specific and non-specific components of the binding phenomenon can be characterized by the same criteria as those used in studies performed with natural membranes. The relative ability of distinct sulphonylureas to inhibit the binding of 3H-glibenclamide or 3H-gliquidone to the liposomes parallels their relative potency as insulin secretagogues. It is proposed that the insertion of hypoglycaemic sulphonylureas into the phospholipid domain of the B cell membrane could represent a primary event in the mechanism by which these agents stimulate insulin release.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Malaisse WJ, Mahy M, Brisson GR, Malaisse-Lagae F (1972) The stimulus-secretion coupling of glucose-induced insulin release. VIII. Combined effects of glucose and sulfonylureas. Eur J Clin Invest 2: 85–90
Lebrun P, Malaisse WJ, Herchuelz A (1982) Modalities of gliclazide-induced Ca2+ influx into the pancreatic B cell. Diabetes 31: 1010–1075
Henquin JC (1980) Tolbutamide stimulation and inhibition of insulin release: studies of the underlying ionic mechanisms in isolated rat islets. Diabetologia 18: 151–160
Henquin JC, Meissner HP (1982) Opposite effects of tolbutamide and diazoxide on 86Rb fluxes and membrane potential in pancreatic B-cells. Biochem Pharmacol 31: 1407–1415
Meissner HP, Preissler M, Henquin JC (1980) Possible ionic mechanisms of the electrical activity induced by glucose and tolbutamide in pancreatic B cells. In: Waldhäusl WK (ed) Diabetes. Excerpta Medica, Amsterdam, pp 166–171
Hellman B (1981) Tolbutamide-stimulation of 45Ca fluxes in microdissected pancreatic islets rich in B-cells. Molec Pharmacol 20: 83–88
Malaisse WJ, Hubinont C, Lebrun P, Herchuelz A, Couturier E, Deleers M, Malaisse-Lagae F, Sener A (1983) Mode of action of hypoglycemic sulfonylureas in the pancreatic B cell: coinciding and conflicting views. In: Serrano-Rios M, Krall LP (eds) Clinical and pharmacological activities of sulfonylurea drugs. Excerpta Medica, Amsterdam pp 24–38
Hellman B, Sehlin J, Täljedal IB (1971) The pancreatic β cell recognition of insulin secretagogues. II. Site of action of tolbutamide. Biochem Biophys Res Commun 45: 1384–1388
Hellman B (1974) Factors affecting the uptake of glibenclamide in microdissected pancreatic islets rich in β-cells. Pharmacology 11: 257–267
Hellman B, Täljedal IB (1979) Effects of sulfonylurea derivatives on pancreatic β cells. In: Hasselblatt A, Bruchhausen FV (eds) Insulin II. Springer Verlag, Berlin Heidelberg New York, pp 175–194
Kaubisch N, Hammer R, Wollheim C, Renold AE, Offord RE (1982) Specific receptors for sulfonylureas in brain and in a β-cell tumor of the rat. Biochem Pharmacol 31: 1171–1174
Orci L, Ravazzola M, Amherdt M, Malaisse-Lagae F (1974) The β cell boundary. In: Malaisse WJ, Pirart J (eds) Diabetes. Excerpta Medica, Amsterdam, pp 104–118
Deleers M, Malaisse WJ (1980) Ionophore-mediated calcium exchange diffusion in liposomes. Biochem Biophys Res Commun 95: 650–657
Szoka F, Papahadjopoulos D (1978) Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci USA 75: 4194–4198
Sehlin J (1973) Evidence for specific binding of tolbutamide to the plasma membrane of the pancreatic B cells. Acta Diabetol lat 5: 1052–1060
Täljedal IB (1974) Uptake of glibornuride by microdissected pancreatic islets. Hormone Res 5: 211–216
Hellman B, Sehlin J, Täljedal IB (1973) The pancreatic B cell recognition of insulin secretagogues. IV. Islet uptake of sulfonylurea. Diabetologia 9: 210–216
Malaisse WJ, Lebrun P, Herchuelz A (1982) Ionic determinants of bioelectrical activity in the pancreatic B-cell. Pflügers Arch 395: 201–203
Deleers M, Gelbcke M, Malaisse WJ (1983) Transport of Pr3+ by hypoglycemic sulfonylureas across liposomal membranes. FEBS Lett 151: 269–279
Philips MC (1972) The physical state of phospholipids and cholesterol in monolayers, bilayers and membranes. Progr Surf Membrane Sci 5: 139–221
Singer SJ (1975) Architecture and topography of biologic membranes. In: Weissmann G, Clairbone R (eds) Cell membranes; biochemistry, cell biology and pathology. HP Publishing, New York, pp 35–44
Montague W, Parkin EN (1980) Changes in membrane lipids of the β-cell during insulin secretion. In: Malaisse WJ, Täljedal IB (eds) Biochemistry and biophysics of the pancreatic B-cell. Horm Metab Res (Suppl) 10:153–157
Szoka F, Papahadjopoulos D (1980) Comparative properties and methods of preparation of lipid vesicles. Ann Rev Biophys Bioeng 9: 467–508
Deleers M, Malaisse WJ (1982) Binding of tumor-promoting and biologically inactive phorbol esters to artificial membranes. Cancer Lett 17: 135–140
Hellman B (1974) Potentiating effects of drugs on the binding of glibenclamide to pancreatic beta cells. Metabolism 23: 839–846
Malaisse WJ, Leclercq-Meyer V (1972) Insulinotropic action of a new sulphonylurea: gliclazide. Rev Europ Etud Clin Biol 17: 310–314
Herchuelz A, Malaisse WJ (1973) Insulinotropic potency of glipizide in vitro. Diabetologia 9: 309–310
Puls W, Keup U, Frerichs M (1974) Beeinflussung der Glykämie und Insulinämie unter Kohlenhydratbelastung durch Pro-Diaban® an gesunden Versuchspersonen. In: Schöffling K, Kroneberg G, Laudahn G (eds) Pro-Diaban. F. K. Schattauer, Stuttgart, pp 99–106
Loubatieres A, Loubatieres-Mariani MM (1974) Experimental study of the betacytotropic and betacytotrophic action of glisoxepide (Pro-Diaban). In: Schöffling K, Kroneberg G, Laudahn G (eds) Pro-Diaban, F. K. Schattauer, Stuttgart, pp 53–63
Haupt E, Köberich W, Beyer J, Schöffling K (1971) Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects. Diabetologia 7: 449–454
Haupt EK, Küllmer G, Schöffling K (1976) Pharmacodynamics of glurenorm. Diab Croatica 5: 373–391
Raptis S, Laube H, Katsilambros N, Hinz M, Rothmann G, Pfeiffer EF (1974) Tierexperimentelle und klinische Untersuchungen mit dem neuen Sulfonylharnstoff Glisoxepid (Pro-Diaban). In: Schöffling K, Kroneberg G, Laudahn G (eds) Pro-Diaban, F. K. Schattauer, Stuttgart, pp 73–82
Zilker T, Lüders L, Bottermann P (1975) Vergleichende Anwendung von Gliquidone und Tolbutamid nach intravenöser Gabe. Münch Med Wochenschr 117: 1421–1422
Zilker T, Waldthaler A, Ermler R, Bottermann P (1975) Wirkung von Gliquidon und Glibenclamid nach oraler Anwendung. Münch Med Wochenschr 117: 1423–1424
Balant L (1981) Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin Pharmacokin 6: 215–241
Bellens R (1961) Contribution à l'étude des mécanismes d'action des drogues hypoglycémiantes. Acta Endocrinol (Kbh) supplem 61
Malaisse W, Bellens R, Franckson JRM (1964) Comparaison de l'action de deux drogues hypoglycémiantes sur la glycémie et l'assimilation glucidique du chien normal. Arch Int Pharmacodyn Ther 149: 290–295
Schneider JA, Salgado ED, Jaeger D, Delahunt C (1959) The pharmacology of chlorpropamide. Ann NY Acad Sci 74: 427–441
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Deleers, M., Malaisse, W.J. Binding of hypoglycaemic sulphonylureas to an artificial phospholipid bilayer. Diabetologia 26, 55–59 (1984). https://doi.org/10.1007/BF00252264
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF00252264